JP7387630B2 - Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体 - Google Patents
Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体 Download PDFInfo
- Publication number
- JP7387630B2 JP7387630B2 JP2020554235A JP2020554235A JP7387630B2 JP 7387630 B2 JP7387630 B2 JP 7387630B2 JP 2020554235 A JP2020554235 A JP 2020554235A JP 2020554235 A JP2020554235 A JP 2020554235A JP 7387630 B2 JP7387630 B2 JP 7387630B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- synthesis
- compound
- amino
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841015818 | 2018-04-26 | ||
| IN201841015818 | 2018-04-26 | ||
| PCT/IB2019/053443 WO2019207538A1 (en) | 2018-04-26 | 2019-04-26 | Pyridazine derivatives as smarca2/4 degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520372A JP2021520372A (ja) | 2021-08-19 |
| JP2021520372A5 JP2021520372A5 (https=) | 2022-05-09 |
| JP7387630B2 true JP7387630B2 (ja) | 2023-11-28 |
Family
ID=68295093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020554235A Active JP7387630B2 (ja) | 2018-04-26 | 2019-04-26 | Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12371426B2 (https=) |
| EP (1) | EP3784665A4 (https=) |
| JP (1) | JP7387630B2 (https=) |
| CN (1) | CN112771038B (https=) |
| CA (1) | CA3118354A1 (https=) |
| SG (1) | SG11202104495YA (https=) |
| WO (1) | WO2019207538A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022547530A (ja) * | 2019-09-12 | 2022-11-14 | オーリジーン ディスカバリー テクノロジーズ リミテッド | Ｓｍａｒｃａ２／４デグレーダに対する応答者を同定するための方法 |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11771697B2 (en) * | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
| CN113874016A (zh) | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| JP2022533260A (ja) * | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| JP2023511471A (ja) * | 2019-10-28 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二官能性化合物 |
| JP2023511472A (ja) * | 2019-10-29 | 2023-03-20 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のための二官能性化合物 |
| CN110790746B (zh) * | 2019-11-18 | 2020-10-30 | 南京恒通医药开发有限公司 | 一种利用微通道反应器连续化制备泊马度胺的合成工艺 |
| EP4081308A4 (en) * | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021142247A1 (en) | 2020-01-10 | 2021-07-15 | Amgen Inc. | Smarca2-vhl degraders |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4096651A4 (en) | 2020-01-29 | 2024-01-24 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| US12599671B2 (en) | 2020-02-12 | 2026-04-14 | Dana-Farber Cancer Institute, Inc. | Compounds, compositions, and methods for protein degradation |
| WO2021207291A1 (en) * | 2020-04-06 | 2021-10-14 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US11739101B2 (en) | 2020-05-06 | 2023-08-29 | Nurix Therapeutics, Inc. | Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| US12570650B2 (en) * | 2020-08-04 | 2026-03-10 | Aurigene Oncology Limited | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
| JP7723743B2 (ja) * | 2020-11-20 | 2025-08-14 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| EP4259144A4 (en) * | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| CN117337178A (zh) * | 2021-05-10 | 2024-01-02 | 福宏治疗公司 | 化合物及其用途 |
| KR20240004983A (ko) * | 2021-05-10 | 2024-01-11 | 포그혼 쎄라퓨틱스 인크. | 화합물 및 이의 용도 |
| US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| CN115611881B (zh) * | 2021-07-13 | 2024-09-20 | 复旦大学 | 一种合成新型vhl配体4-f-vh032的方法 |
| KR20240046498A (ko) | 2021-08-09 | 2024-04-09 | 제넨테크, 인크. | Brm의 조절에 사용하기 위한 페놀 유도체 |
| US20250145609A1 (en) * | 2022-02-09 | 2025-05-08 | Aurigene Oncology Limited | 3-substituted pyridazine compounds as smarca2 and/or smarca4 degraders |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| WO2024064328A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| WO2024064316A1 (en) | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 inhibitors and uses thereof |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
| PE20260307A1 (es) | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| PE20260301A1 (es) | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| CN121816356A (zh) * | 2023-07-28 | 2026-04-07 | 甘李药业股份有限公司 | 一种选择性降解smarca2/4的化合物及其应用 |
| CN118406019B (zh) * | 2024-07-02 | 2024-09-20 | 苏州源起材料科技有限公司 | 一种噻唑化合物生物医药砌块的合成方法 |
| WO2026061475A1 (zh) * | 2024-09-19 | 2026-03-26 | 标新生物医药科技(上海)有限公司 | 含有芳基取代杂芳基的双功能蛋白降解剂及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
| JP2018510851A (ja) | 2015-02-25 | 2018-04-19 | ジェネンテック， インコーポレイテッド | 治療用ピリダジン化合物およびその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190300521A1 (en) * | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| US11771697B2 (en) * | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
| PH12022550578A1 (en) * | 2019-09-12 | 2024-02-19 | Aurigene Discovery Tech Ltd | Method for identifying responders to smarca2/4 degraders |
-
2019
- 2019-04-26 EP EP19792591.0A patent/EP3784665A4/en active Pending
- 2019-04-26 CA CA3118354A patent/CA3118354A1/en active Pending
- 2019-04-26 JP JP2020554235A patent/JP7387630B2/ja active Active
- 2019-04-26 SG SG11202104495YA patent/SG11202104495YA/en unknown
- 2019-04-26 WO PCT/IB2019/053443 patent/WO2019207538A1/en not_active Ceased
- 2019-04-26 US US17/050,792 patent/US12371426B2/en active Active
- 2019-04-26 CN CN201980041999.5A patent/CN112771038B/zh active Active
-
2024
- 2024-03-19 US US18/609,175 patent/US20240270734A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018510851A (ja) | 2015-02-25 | 2018-04-19 | ジェネンテック， インコーポレイテッド | 治療用ピリダジン化合物およびその使用 |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2017201449A1 (en) | 2016-05-20 | 2017-11-23 | Genentech, Inc. | Protac antibody conjugates and methods of use |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022547530A (ja) * | 2019-09-12 | 2022-11-14 | オーリジーン ディスカバリー テクノロジーズ リミテッド | Ｓｍａｒｃａ２／４デグレーダに対する応答者を同定するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019207538A1 (en) | 2019-10-31 |
| CA3118354A1 (en) | 2019-10-31 |
| US20240270734A1 (en) | 2024-08-15 |
| JP2021520372A (ja) | 2021-08-19 |
| EP3784665A4 (en) | 2022-01-26 |
| SG11202104495YA (en) | 2021-05-28 |
| CN112771038A (zh) | 2021-05-07 |
| US12371426B2 (en) | 2025-07-29 |
| EP3784665A1 (en) | 2021-03-03 |
| CN112771038B (zh) | 2024-09-24 |
| US20210253564A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7387630B2 (ja) | Ｓｍａｒｃａ２／４分解剤としてのピリダジン誘導体 | |
| CN112262139B (zh) | 作为激酶抑制剂的氨基吡咯并三嗪 | |
| CN103842340B (zh) | 核转运调节剂及其应用 | |
| JP6560436B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールスルホンアミド誘導体化合物及びこれを含有する薬剤学的組成物 | |
| CN107108581B (zh) | 作为强效rock抑制剂的回接苯甲酰胺衍生物 | |
| CN105073741B (zh) | 作为rock抑制剂的酞嗪酮及异喹啉酮 | |
| CN114727991B (zh) | 作为Kv1.3钾SHAKER通道阻断剂的芳基亚甲基杂环化合物 | |
| CN112424188A (zh) | 作为parp7抑制剂的哒嗪酮 | |
| JP7483678B2 (ja) | Ｐａｄ４阻害剤としての置換ベンズイミダゾール | |
| JP2025186255A (ja) | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリール複素環式化合物 | |
| CA3042710A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors | |
| TW202413351A (zh) | 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法 | |
| CA2954976A1 (en) | Spirocycloheptanes as inhibitors of rock | |
| CN112673000B (zh) | 作为受体相互作用蛋白激酶1抑制剂(ripk1)的1h-吲唑甲酰胺 | |
| CN116490184A (zh) | 用于抑制egfr突变癌症的化合物及其药物用途 | |
| JP2022533147A (ja) | 芳香族アミン類のａｒ及びｂｅｔを標的とするタンパク質分解キメラ化合物及び使用 | |
| CN114728177B (zh) | 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物 | |
| AU2015306458B2 (en) | Indazoles | |
| WO2015125785A1 (ja) | 複数置換基を有するピラゾロン誘導体 | |
| TW202140499A (zh) | 巨環ｒｉｐ２－激酶抑制劑 | |
| KR20220014952A (ko) | 안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도 | |
| TW202348225A (zh) | Myc家族原癌基因蛋白之調節劑 | |
| RU2817356C1 (ru) | Соединение для разрушения андрогенового рецептора и его фармацевтическое применение | |
| WO2024035688A1 (en) | Macrocyclic bcl6 degraders | |
| TW202409011A (zh) | 人類呼吸道融合病毒及間質肺病毒抑制劑 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220425 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220425 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230313 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230302 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230612 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230628 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231016 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231115 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7387630 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |